The Hormonal Receptor Status in Breast Cancer can be Altered by Neoadjuvant Chemotherapy: A Meta-Analysis

REFERENCES

• De Lena M, Zucali R, Viganotti G, Valagussa P, Bonadonna G. Combined chemotherapy-radiotherapy approach in locally advanced (t3b-t4) breast cancer. Cancer Chemother Pharmacol 1978;1:53–59.
   PubMed Web of Science ®Google Scholar
• Burcombe RJ, Makris A, Richman PI, Daley FM, Noble S, Pittam M, Wright D, Allen SA, Dove J, Wilson GD. Evaluation of er, pgr, her-2 and ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 2005;92:147–155.
   PubMed Web of Science ®Google Scholar
• Precht LM, Lowe KA, Atwood M, Beatty JD. Neoadjuvant chemotherapy of breast cancer: Tumor markers as predictors of pathologic response, recurrence, and survival. Breast J 2010;16:362–368.
   PubMed Web of Science ®Google Scholar
• Tan MC, Al Mushawah F, Gao F, Aft RL, Gillanders WE, Eberlein TJ, Margenthaler JA. Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer. Am J Surg 2009;198:520–525.
   PubMed Web of Science ®Google Scholar
• Caudle AS, Gonzalez-Angulo AM, Hunt KK, Liu P, Pusztai L, Symmans WF, Kuerer HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010;28:1821–1828.
   PubMed Web of Science ®Google Scholar
• Lee SH, Chung MA, Quddus MR, Steinhoff MM, Cady B. The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer. Am J Surg 2003;186:348–350.
   PubMed Web of Science ®Google Scholar
• Makris A, Powles TJ, Allred DC, Ashley SE, Trott PA, Ormerod MG, Titley JC, Dowsett M. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot study. Breast Cancer Res Treat 1999;53:51–59.
   PubMed Web of Science ®Google Scholar
• Arens N, Bleyl U, Hildenbrand R. Her2/neu, p53, ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer. Virchows Arch 2005;446:489–496.
   PubMed Web of Science ®Google Scholar
• Lee J, Im YH, Lee SH, Cho EY, Choi YL, Ko YH, Kim JH, Nam SJ, Kim HJ, Ahn JS, Park YS, Lim HY, Han BK, Yang JH. Evaluation of er and ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer. Cancer Chemother Pharmacol 2008;61:569–577.
   PubMed Web of Science ®Google Scholar
• Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009;20:1953–1958.
   PubMed Web of Science ®Google Scholar
• Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, Clemons MJ. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 2009;20:1499–1504.
   PubMed Web of Science ®Google Scholar
• Amir E, Clemons M. Should a biopsy be recommended to confirm metastatic disease in women with breast cancer? Lancet Oncol 2009;10:933–935.
   PubMed Web of Science ®Google Scholar
• Karlsson E, Lindström LS, Wilking U, Skoog L, Johansson U, Bergh J. Discordance in hormone receptor status in breast cancer during tumor progression [Abstract]. J Clin Oncol 2010: 1009.
   Google Scholar
• Kasami M, Uematsu T, Honda M, Yabuzaki T, Sanuki J, Uchida Y, Sugimura H. Comparison of estrogen receptor, progesterone receptor and her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy. Breast 2008;17:523–527.
   PubMed Web of Science ®Google Scholar
• Morris DM, Edwards J, Gelder F. Hormonal receptors in locally advanced breast cancer: Change with response to neoadjuvant chemotherapy? J Surg Oncol 1991;46:156–158.
   PubMed Web of Science ®Google Scholar
• Lo SS, Wang HC, Shyr YM, Lui WY. Can the hormonal receptor status of primary breast cancer be altered by neoadjuvant chemotherapy? J Surg Oncol 1994;57:94–96.
   PubMed Web of Science ®Google Scholar
• Jain V, Landry M, Levine EA. The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma. Am Surg 1996;62:162– 165.
   PubMed Web of Science ®Google Scholar
• Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ. Breast cancer response to neoadjuvant chemotherapy: Predictive markers and relation with outcome. Br J Cancer 2003;88:406–412.
   PubMed Web of Science ®Google Scholar
• Taucher S, Rudas M, Gnant M, Thomanek K, Dubsky P, Roka S, Bachleitner T, Kandioler D, Wenzel C, Steger G, Mittlbock M, Jakesz R. Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. Endocrine-Related Cancer 2003;10:91–98.
   PubMed Web of Science ®Google Scholar
• Piper GL, Patel NA, Patel JA, Malay MB, Julian TB. Neoadjuvant chemotherapy for locally advanced breast cancer results in alterations in preoperative tumor marker status. Am Surg 2004;70:1103–1106.
   PubMed Web of Science ®Google Scholar
• Rody A, Karn T, Gatje R, Kourtis K, Minckwitz G, Loibl S, Munnes M, Ruckhaberle E, Holtrich U, Kaufmann M, Ahr A. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures. Zentralbl Gynakol 2006;128:76–81.
   PubMedGoogle Scholar
• Hirata T, Shimizu C, Yonemori K, Hirakawa A, Kouno T, Tamura K, Ando M, Katsumata N, Fujiwara Y. Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer. Br J Cancer 2009;101:1529– 1536.
   PubMed Web of Science ®Google Scholar